

Application No.: 09/657,431

2

Docket No.: 500862001400

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended): A modified antiangiogenic peptide comprising a ~~peptide corresponding to a region of mammalian plasminogen, a kringle 5 peptide~~ and a reactive group which reacts with amino groups, hydroxyl groups, or thiol groups on blood components to form stable covalent bonds wherein said reactive group is selected from the group consisting of succinimidyl and maleimido groups.

Claim 2 (cancelled)

Claim 3 (currently amended): The modified peptide of claim ~~[[2]]~~ 1 wherein ~~[[said]]~~ the modified peptide is reactive with blood proteins.

Claim 4 (previously presented): The modified peptide of claim 3, wherein the modified peptide is reactive with a thiol group on a blood protein.

Claim 5 (currently amended): The modified peptide of claim ~~[[2]]~~ 1 wherein the modified peptide is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9.

Claim 6 (currently amended): The modified peptide of claim ~~[[2]]~~ 1 wherein the modified peptide is selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16.

Claims 7-9 (cancelled)

sf-1832303

**Application No.: 09/657,431****3****Docket No.: 500862001400**

**Claim 10 (previously presented):** A modified kringle 5 peptide comprising a kringle 5 peptide and a maleimido group which reacts with a thiol group on human serum albumin to form a covalent bond.

**Claim 11 (previously presented):** The modified kringle 5 peptide of claim 10, wherein said kringle 5 peptide is selected from SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9.

**Claim 12 (previously presented):** The modified kringle 5 peptide of claim 10, wherein said kringle 5 peptide is selected from SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16.

**Claims 13-18 (cancelled)**

**Claim 19 (original):** A modified kringle 5 peptide selected from the group consisting of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH<sub>2</sub>; NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub>; Nac-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub>; NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub>; NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-NH<sub>2</sub>; NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Ns-MPA)-NH<sub>2</sub>; (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> and (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.

sf-1832303

Application No.: 09/657,431

4

Docket No.: 500862001400

Claim 20 (original): A modified kringle 5 peptide selected from the group consisting of: NAc-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH<sub>2</sub>; (MPA-AEEA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>; (MPA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>; NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH<sub>2</sub>; (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>; and (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.

Claim 21 (previously presented): A modified kringle 5 peptide selected from the group consisting of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-(Nε-MPA)-NH<sub>2</sub>; (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH<sub>2</sub>; (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH<sub>2</sub>; NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH<sub>2</sub>; (MPA-AEEA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>; (MPA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>; NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-(Nε-MPA)-NH<sub>2</sub>; (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH<sub>2</sub>; (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH<sub>2</sub>; NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-AEEA-MPA)-NH<sub>2</sub>; and NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-AEEA<sub>n</sub>-MPA)-NH<sub>2</sub>.

sf-1832303